Draurio Barreira

Draurio Barreira

Auto-generated profile, based on publicly available information

Draurio Barreira

Ministério da Saúde, Brasil

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2017 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
WRWilliam E Rudgard
William E Rudgard
CECarlton A Evans
Carlton A Evans
SSSedona Sweeney
Sedona Sweeney
TWTom Wingfield
Tom Wingfield
KLKnut Lönnroth
Knut Lönnroth
DBDelia Boccia
Delia Boccia
Illness-related costs for patients with tuberculosis (TB) ≥20% of pre-illness annual household income predict adverse treatment outcomes and have been termed “catastrophic.” Social protection initiatives, including cash transfers, are endorsed to help prevent catastrophic costs. With this aim, cash transfers may either be provided to defray TB-related costs of households with a confirmed TB diagnosis (termed a “TB-specific” approach); or to increase income of households with high TB risk to strengthen their economic resilience (termed a “TB-sensitive” approach). The impact of cash transfers provided with each of these approaches might vary. We undertook an economic modelling study from the patient perspective to compare the potential of these 2 cash transfer approaches to prevent catastrophic costs. Model inputs for 7 low- and middle-income countries (Brazil, Colombia, Ecuador, Ghana, Mexico, Tanzania, and Yemen) were retrieved by literature review and included countries' mean patient TB-related costs, mean household income, mean cash transfers, and estimated TB-specific and TB-sensitive target populations. Analyses were completed for drug-susceptible (DS) TB-related costs in all 7 out of 7 countries, and additionally for drug-resistant (DR) TB-related costs in 1 of the 7 countries with available data. All cost data were reported in 2013 international dollars ($). The target population for TB-specific cash transfers was poor households with a confirmed TB diagnosis, and for TB-sensitive cash transfers was poor households already targeted by countries’ established poverty-reduction cash transfer programme. Cash transfers offered in countries, unrelated to TB, ranged from $217 to $1,091/year/household. Before cash transfers, DS TB-related costs were catastrophic in 6 out of 7 countries. If cash transfers were provided with a TB-specific approach, alone they would be insufficient to prevent DS TB catastrophic costs in 4 out of 6 countries, and when increased enough to prevent DS TB catastrophic costs would require a budget between $3.8 million (95% CI: $3.8 million–$3.8 million) and $75 million (95% CI: $50 million–$100 million) per country. If instead cash transfers were provided with a TB-sensitive approach, alone they would be insufficient to prevent DS TB-related catastrophic costs in any of the 6 countries, and when increased enough to prevent DS TB catastrophic costs would require a budget between $298 million (95% CI: $219 million–$378 million) and $165,367 million (95% CI: $134,085 million–$196,425 million) per country. DR TB-related costs were catastrophic before and after TB-specific or TB-sensitive cash transfers in 1 out of 1 countries. Sensitivity analyses showed our findings to be robust to imputation of missing TB-related cost components, and use of 10% or 30% instead of 20% as the threshold for measuring catastrophic costs. Key limitations were using national average data and not considering other health and social benefits of cash transfers. A TB-sensitive cash transfer approach to increase all poor households’ income may have broad benefits by reducing poverty, but is unlikely to be as effective or affordable for preventing TB catastrophic costs as a TB-specific cash transfer approach to defray TB-related costs only in poor households with a confirmed TB diagnosis. Preventing DR TB-related catastrophic costs will require considerable additional investment whether a TB-sensitive or a TB-specific cash transfer approach is used.

6 August 2018 in The Brazilian Journal of Infectious Diseases
Verified
Journal Article
Open access
RGRegina Gayoso
Regina Gayoso
MDMargareth Pretti Dalcolmo
Margareth Pretti Dalcolmo
JBJosé Ueleres Braga
José Ueleres Braga
DBDraurio Barreira
Draurio Barreira
To determine the main predictors of death in multidrug-resistant (MDRTB) patients from Brazil. Retrospective cohort study, a survival analysis of patients treated between 2005 and 2012. Of 3802 individuals included in study, 64.7% were men, mean age was 39 (1-93) years, and 70.3% had bilateral pulmonary disease. Prevalence of human immunodeficiency virus (HIV) was 8.3%. There were 479 (12.6%) deaths. Median survival time was 1452 days (4 years). Factors associated with increased risk of death were age greater than or equal to 60 years (hazard rate [HR] = 1.6, confidence interval [CI] = 1.15-2.2), HIV co-infection (HR = 1.46; CI = 1.05-1.96), XDR resistance pattern (HR = 1.74, CI = 1.05-2.9), beginning of treatment after failure (HR = 1.72, CI = 1.27-2.32), drug abuse (HR = 1.64, CI = 1.22-2.2), resistance to ethambutol (HR = 1.30, CI = 1.06-1.6) or streptomycin (HR = 1.24, CI = 1.01-1.51). Mainly protective factors were presence of only pulmonary disease (HR = 0.57, CI = 0.35-0.92), moxifloxacin use (HR = 0.44, CI = 0.25-0.80), and levofloxacin use (HR = 0.75; CI = 0.60-0.94). A more comprehensive approach is needed to manage MDRTB, addressing early diagnostic, improving adhesion, and comorbidities, mainly HIV infection and drug abuse. The latest generation quinolones have an important effect in improving survival in MDRTB.

1 January 2024 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
PDF file
EMEthel Maciel
Ethel Maciel
MSMauro Niskier Sanchez
Mauro Niskier Sanchez
ADAlda Maria Da-Cruz
Alda Maria Da-Cruz
DNDraurio Barreira Cravo Neto
Draurio Barreira Cravo Neto
NLNísia Verônica Trindade Lima
Nísia Verônica Trindade Lima
The Unified Health System (Sistema Único de Saúde, SUS) offers universal systemic healthcare to all citizens resident in Brazil. Unfortunately, the system has also suffered years of underfunding, while Brazil is going through a very particular epidemiological transition, involving a triple challenge in the field of healthcare: at the same time as chronic non-communicable diseases, as well as accidents and violence are important public health issues, so are communicable diseases, still constituting an unacceptable burden on the health system, impacting population health.

29 February 2024 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Closed access
AMAngélica Espinosa Miranda
Angélica Espinosa Miranda
PGPâmela Cristina Gaspar
Pâmela Cristina Gaspar
MSMarcos Andre Schorner
Marcos Andre Schorner
FBFernando Hartmann Barazzetti
Fernando Hartmann Barazzetti
GDGuilherme Borges Dias
Guilherme Borges Dias
BGBrazilian Surveillance for STIs in Pregnant Women Group
Brazilian Surveillance for STIs in Pregnant Women Group

1 January 2024 in Revista do Instituto de Medicina Tropical de São Paulo
Verified
Journal Article
Open access
PDF file
ISIsabella Nepomuceno de Souza
Isabella Nepomuceno de Souza
APAna Roberta Pati Pascom
Ana Roberta Pati Pascom
MSMatheus Funke Spinelli
Matheus Funke Spinelli
GDGuilherme Borges Dias
Guilherme Borges Dias
DBDraurio Barreira
Draurio Barreira
AMAngélica Espinosa Miranda
Angélica Espinosa Miranda
The worldwide monkeypox (mpox) outbreak in 2022 showed a high frequency of sexually transmitted infections (STI). A cross-sectional study was carried out using secondary data from the Brazilian official mpox surveillance systems. A total of 10,169 mpox cases were identified, with a median age of 32 years. Among them, 92.3% were male at birth and 57.5% were men who have sex with other men (MSM). Approximately 11% were diagnosed with STI, including 5.8% with syphilis and 2.5% with genital herpes. Individuals aged from 25 to 34 years, MSM, individuals with HIV-positive status, and those manifesting skin eruptions or penile edema were associated with STI. Laboratory investigation for mpox must be implemented as a priority in STI clinics (especially for MSM) to mitigate neglected cases, ensure appropriate treatments, and prevent misdiagnoses.

24 September 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ABAline Benjamin
Aline Benjamin
SCSolange Cesar Cavalcante
Solange Cesar Cavalcante
LJLeda Fátima Jamal
Leda Fátima Jamal
DADenise Arakaki-Sanchez
Denise Arakaki-Sanchez
JLJosué Nazareno De Lima
Josué Nazareno De Lima
VRValeria Rolla
Valeria Rolla
Determine TB-LAM Ag (LAM) is a point of care test developed to diagnose tuberculosis (TB). The aim of this study was to evaluate the diagnostic performance of LAM in people living with HIV using Brazilian public health network algorithm for TB diagnosis. A cross-sectional study design was used to enroll 199 adult patients in two sites in Rio de Janeiro and two in São Paulo. The study enrolled HIV-infected patients with CD4 counts ≤200 cells/mm3 (in the Alere PIMA CD4 assay at study screening), patients coughing for at least 2 weeks or presenting a chest radiography suggestive of TB. LAM, in conjunction with sputum smear microscopy or Xpert MTB/RIF (Xpert) as compared to Mycobacterium tuberculosis culture, which was used as a reference standard. TB prevalence was 24.6%. Overall accuracy of LAM was 79.9% (73.8%-84.9%), positive and negative predictive values were 62.2% (46.1%-75.9%) and 84% (77.5%-88.8%), respectively. The overall LAM sensitivity was 46.9% (33.7%-60.6%) and specificity was 90.7% (84.9%-94.4%). The best performance of LAM was observed among patients with CD4 counts ≤50 cells/mm3 (sensitivity = 70.4% and specificity = 85.9%). When 2 respiratory smears were used in conjunction with LAM, sensitivity increased 22%, as compared to just 2 smears. Furthermore, LAM when used in conjunction with two respiratory smears, was as sensitive as compared to a single one. However, no improvement in TB diagnosis occurred when LAM was used with Xpert as compared to Xpert alone. Among 14 LAM false positive tests, Non-Tuberculosis Mycobacteria were isolated in three cases. LAM is a point of care test that increased TB diagnosis in immunosuppressed HIV-infected patients when used in conjunction with smear microscopy, but not when used with Xpert in Brazilian public health network sites. Use of LAM test should be considered in settings where immunosuppressed HIV patients need rapid TB diagnosis.